Clinical Commander

Back to dossier
neuro.pres.v1PRODUCTION
neuro.pres.v1

Posterior Reversible Encephalopathy Syndrome (PRES)

neurologyacutesubacuteadultpregnancy
Hard-required inputs
0 / 12
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Acute encephalopathy with parieto-occipital vasogenic edema; recognise trigger-removal-reversibility paradigm and avoid BP-overcorrection ischemic risk (Fugate Lancet Neurol 2015 PMID 26184985)

Inputs
0
Actions
0
Advance rule
Set
Advance when

PRES suspected on syndromic + imaging grounds

Patient inputs (16)

PRES occurs across age range; pediatric and elderly both reported (Fugate Lancet Neurol 2015 PMID 26184985)

Eclampsia / postpartum-PRES is a high-prevalence substrate; pregnancy status drives MgSO4 + delivery pathway (Triplett Pract Neurol 2022 PMID 35046115)

Pregnancy / postpartum status determines eclampsia pathway + MgSO4 indication (Triplett Pract Neurol 2022 PMID 35046115)

Cyclosporine / tacrolimus / bevacizumab / sorafenib / sunitinib / oxaliplatin / cisplatin — drug-PRES trigger requiring drug-removal / mTOR switch (Fugate Lancet Neurol 2015 PMID 26184985)

MRI FLAIR confirms vasogenic edema; DWI distinguishes cytotoxic-PRES variant (restriction = worse prognosis) (Bartynski AJNR 2008 PMID 18403560; Fischer/Schmutzhard J Neurol 2017 PMID 28054130)

Baseline + monitoring for HUS/TTP-driven PRES (thrombotic microangiopathy phenotype) (Fugate Lancet Neurol 2015 PMID 26184985)

Severe hypocalcemia / hypomagnesemia are independent PRES triggers; renal failure drives uremic-PRES (Fugate Lancet Neurol 2015 PMID 26184985)

HELLP / hepatic involvement screen in peripartum PRES; AED hepatic-dosing baseline (Triplett Pract Neurol 2022 PMID 35046115)

Baseline coag in case of intracerebral hemorrhage complication of PRES (Fugate Lancet Neurol 2015 PMID 26184985)

GCS<13 marks severe-PRES — ICU triage trigger (Fugate Lancet Neurol 2015 PMID 26184985)

Severe HTN (often >160/100) is the most common trigger (~60%); target SBP 140-150 first 24h (Fugate Lancet Neurol 2015 PMID 26184985; Hinchey NEJM 1996 PMID 8559202)

DBP component of MAP / autoregulatory-breakthrough hypothesis (Bartynski AJNR 2008 PMID 18403560)

SLE / scleroderma / vasculitis flare can precipitate PRES (Fugate Lancet Neurol 2015 PMID 26184985)

Allograft rejection + calcineurin-inhibitor combination is a high-substrate PRES trigger (Fischer/Schmutzhard J Neurol 2017 PMID 28054130)

Sepsis-associated PRES described — endothelial dysfunction pathway (Fischer/Schmutzhard J Neurol 2017 PMID 28054130)

MRV or CTV essential to exclude CVT mimic in headache + seizure + edema presentation (Fugate Lancet Neurol 2015 PMID 26184985)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (10)

10 need judgement
  • informationallife_threateningstatus_epilepticus_PRES
    Status epilepticus in PRES — clinical or electrographic (Fugate Lancet Neurol 2015 PMID 26184985)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningintracranial_hemorrhage_complication_PRES
    Cerebral hemorrhage on initial or follow-up imaging (10-15% of PRES) (Fugate Lancet Neurol 2015 PMID 26184985)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningeclampsia_PRES
    Peripartum / postpartum PRES with eclampsia phenotype (HTN + proteinuria + seizure) (Triplett Pract Neurol 2022 PMID 35046115)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverecytotoxic_PRES_on_DWI
    DWI restriction within PRES territory — cytotoxic-edema variant (Bartynski AJNR 2008 PMID 18403560)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererefractory_severe_HTN_PRES
    SBP >180 despite two IV antihypertensives in PRES — refractory hypertensive crisis (Fugate Lancet Neurol 2015 PMID 26184985)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverebrainstem_PRES
    Atypical-PRES with brainstem / deep gray / cerebellar involvement (Bartynski AJNR 2008 PMID 18403560)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveretma_driven_PRES
    PRES with concurrent thrombotic microangiopathy (schistocytes + thrombocytopenia + LDH; ADAMTS13 confirms TTP) (Fugate Lancet Neurol 2015 PMID 26184985)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatecni_or_chemo_driven_PRES
    PRES in patient on cyclosporine / tacrolimus or chemotherapy (bevacizumab / sorafenib / sunitinib / oxaliplatin / cisplatin) (Fugate Lancet Neurol 2015 PMID 26184985)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatesevere_hypocalcemia_or_hypomagnesemia_PRES
    Severe hypocalcemia (<7.0 mg/dL) or hypomagnesemia (<1.0 mg/dL) as electrolyte trigger for PRES (Fugate Lancet Neurol 2015 PMID 26184985)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderaterecurrent_PRES
    Recurrent PRES (5-10% reported) — most commonly in continued CNI exposure, persistent HTN, or repeated chemotherapy (Fischer/Schmutzhard J Neurol 2017 PMID 28054130)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

TREATMENTrequiredDrives risk stratification
Loading…

Recommended regimen

PRES trigger-removal + BP-control + seizure-management ladder (Fugate Lancet Neurol 2015 PMID 26184985 + Triplett Pract Neurol 2022 PMID 35046115 + Hinchey NEJM 1996 PMID 8559202)
axis: pres_trigger_removal_bp_seizure_bundlestep 1 - Step 1 — Identify + remove trigger (Fugate Lancet Neurol 2015 PMID 26184985)
Selected step "Step 1 — Identify + remove trigger (Fugate Lancet Neurol 2015 PMID 26184985)" — PRES confirmed on imaging + trigger identified (severe HTN, CNI, chemotherapy, eclampsia, autoimmune flare, transplant rejection, hypocalcemia, hypomagnesemia, sepsis, HUS/TTP)
  • sirolimus
    contraindication substitute
    mTOR_inhibitor
    Per transplant protocol (target trough 4-12 ng/mL) • PO • daily
    triggers: CNI_driven_PRES, transplant_rejection_with_PRES
    Switch from cyclosporine / tacrolimus to mTOR inhibitor (sirolimus or everolimus) is the preferred trigger-removal strategy in CNI-PRES; lower PRES recurrence risk (Fischer/Schmutzhard J Neurol 2017 PMID 28054130)
    rxcui 35302
  • everolimus
    contraindication substitute
    mTOR_inhibitor
    Per transplant protocol (target trough 3-8 ng/mL) • PO • BID
    triggers: CNI_driven_PRES_alt_to_sirolimus
    mTOR inhibitor alternative when CNI cannot be re-introduced (Fischer/Schmutzhard J Neurol 2017 PMID 28054130)
    rxcui 141704

ed playbook — drug actions (5)

  1. 1. nicardipine
    rxcui 7396
    5 mg/h IV titrate to 15 mg/h • IV • continuous
    trigger: Severe HTN-driven PRES SBP >160-180
    IV nicardipine first-line per Fugate Lancet Neurol 2015 PMID 26184985
  2. 2. labetalol
    rxcui 6185
    20 mg IV bolus q10min • IV • bolus then infusion
    trigger: Alternative or pregnancy-PRES BP control
    Pregnancy-safe per ACOG (Triplett Pract Neurol 2022 PMID 35046115)
  3. 3. lorazepam
    rxcui 6470
    4 mg IV over 2 min, repeat q5min × 2 • IV • bolus
    trigger: Active seizure
    First-line abortive (Fugate Lancet Neurol 2015 PMID 26184985)
  4. 4. levetiracetam
    rxcui 114477
    1500 mg IV load + 1000 mg q12h • IV • BID
    trigger: AED after benzo or for prophylaxis post-seizure
    Levetiracetam preferred — no hepatic interactions (Fugate Lancet Neurol 2015 PMID 26184985)
  5. 5. magnesium sulfate
    rxcui 6585
    4-6 g IV load + 1-2 g/h × 24h • IV • load + continuous
    trigger: Eclampsia overlay
    MgSO4 first-line for eclampsia-PRES (Triplett Pract Neurol 2022 PMID 35046115)

Auto-drafted A&P note

ed

Subjective

- Possible entry pathways: Headache + altered mental status + visual disturbance + seizures + severe HTN (Hinchey NEJM 1996 PMID 8559202; Fugate Lancet Neurol 2015 PMID 26184985); New seizure in transplant recipient on calcineurin inhibitor OR cancer patient on bevacizumab/sorafenib/sunitinib/oxaliplatin/cisplatin (Fugate Lancet Neurol 2015 PMID 26184985); Peripartum / postpartum eclampsia phenotype with seizure or altered mental status (Triplett Pract Neurol 2022 PMID 35046115).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Posterior Reversible Encephalopathy Syndrome (PRES)** (neuro.pres.v1).
Phenotype framing: PRES vs cerebral venous thrombosis (MRV defect) vs RCVS (thunderclap + vasospasm beading on CTA) vs top-of-basilar stroke (DWI restriction in arterial territory) vs autoimmune encephalitis (CSF NMDAR/LGI1) vs HSV encephalitis (CSF HSV PCR; bilateral temporal) vs CNS vasculitis vs hypoglycemia vs drug intoxication (Fugate Lancet Neurol 2015 PMID 26184985)
Scope: Acute encephalopathy with parieto-occipital vasogenic edema; recognise trigger-removal-reversibility paradigm and avoid BP-overcorrection ischemic risk (Fugate Lancet Neurol 2015 PMID 26184985)

No severity triggers fired against current inputs.

Plan

Regimen axis: **PRES trigger-removal + BP-control + seizure-management ladder (Fugate Lancet Neurol 2015 PMID 26184985 + Triplett Pract Neurol 2022 PMID 35046115 + Hinchey NEJM 1996 PMID 8559202)** — step "Step 1 — Identify + remove trigger (Fugate Lancet Neurol 2015 PMID 26184985)".
1. sirolimus Per transplant protocol (target trough 4-12 ng/mL) PO daily (mTOR_inhibitor, contraindication substitute) — Switch from cyclosporine / tacrolimus to mTOR inhibitor (sirolimus or everolimus) is the preferred trigger-removal strategy in CNI-PRES; lower PRES recurrence risk (Fischer/Schmutzhard J Neurol 2017 PMID 28054130)
2. everolimus Per transplant protocol (target trough 3-8 ng/mL) PO BID (mTOR_inhibitor, contraindication substitute) — mTOR inhibitor alternative when CNI cannot be re-introduced (Fischer/Schmutzhard J Neurol 2017 PMID 28054130)

Setting playbook (ed) — Recognise PRES in headache + AMS + visual + seizure + severe HTN OR chemo/immunosuppressant trigger; STAT MRI FLAIR/DWI; initiate BP control (nicardipine/labetalol) targeting SBP 140-150; AED for seizure; ICU triage if severe (Fugate Lancet Neurol 2015 PMID 26184985)
3. nicardipine 5 mg/h IV titrate to 15 mg/h IV continuous — Severe HTN-driven PRES SBP >160-180 (IV nicardipine first-line per Fugate Lancet Neurol 2015 PMID 26184985)
4. labetalol 20 mg IV bolus q10min IV bolus then infusion — Alternative or pregnancy-PRES BP control (Pregnancy-safe per ACOG (Triplett Pract Neurol 2022 PMID 35046115))
5. lorazepam 4 mg IV over 2 min, repeat q5min × 2 IV bolus — Active seizure (First-line abortive (Fugate Lancet Neurol 2015 PMID 26184985))
6. levetiracetam 1500 mg IV load + 1000 mg q12h IV BID — AED after benzo or for prophylaxis post-seizure (Levetiracetam preferred — no hepatic interactions (Fugate Lancet Neurol 2015 PMID 26184985))
7. magnesium sulfate 4-6 g IV load + 1-2 g/h × 24h IV load + continuous — Eclampsia overlay (MgSO4 first-line for eclampsia-PRES (Triplett Pract Neurol 2022 PMID 35046115))

Non-pharmacologic actions:
- STAT neurology consult (Fugate Lancet Neurol 2015 PMID 26184985)
- STAT OB consult if peripartum / postpartum (Triplett Pract Neurol 2022 PMID 35046115)
- Two large-bore IVs; cardiac monitor; SpO2; arterial line if ICU titration (Fugate Lancet Neurol 2015 PMID 26184985)
- AVOID nitroprusside (intracranial steal) — explicit team handoff (Fugate Lancet Neurol 2015 PMID 26184985)
- Halt offending chemo / CNI / immunosuppressant in collaboration with primary service (Fischer/Schmutzhard J Neurol 2017 PMID 28054130)
- HOB 30° if elevated ICP suspected (Fugate Lancet Neurol 2015 PMID 26184985)

AVOID / contraindication checks:
- No_nitroprusside_in_PRES (intracranial steal + increased ICP — AVOID; Fugate Lancet Neurol 2015 PMID 26184985)
- No_over_correction_of_BP_below_baseline_25pct (cerebral autoregulation impaired — ischemic stroke risk; Fugate Lancet Neurol 2015 PMID 26184985)
- No_phenytoin_fosphenytoin_in_cytotoxic_PRES_with_hepatic_dysfunction (use levetiracetam; Fugate Lancet Neurol 2015 PMID 26184985)
- No_routine_corticosteroids_in_PRES (no evidence; potential harm; Fugate Lancet Neurol 2015 PMID 26184985)
- No_re_challenge_with_offending_chemo_or_CNI_without_neurology_consult (Fischer/Schmutzhard J Neurol 2017 PMID 28054130)
- No_warfarin_DOAC_unless_separate_thrombotic_indication (PRES itself is not a thrombotic disease; AED interactions with warfarin require careful management; Triplett Pract Neurol 2022 PMID 35046115)

Monitoring

Regimen monitoring:
- hourly BP during acute titration first 24h target SBP 140 150 (Fugate Lancet Neurol 2015 PMID 26184985)
- daily neuro exam with visual fields during admission (Hinchey NEJM 1996 PMID 8559202)
- serum Ca Mg q4 6h if eclampsia MgSO4 or severe electrolyte trigger (Triplett Pract Neurol 2022 PMID 35046115)
- cEEG continuous if AMS post seizure or status (Fugate Lancet Neurol 2015 PMID 26184985)
- repeat MRI at 1 3 months to confirm edema resolution radiologic diagnostic confirmation (Bartynski AJNR 2008 PMID 18403560)
- CNI trough levels if transplant PRES (Fischer/Schmutzhard J Neurol 2017 PMID 28054130)

Setting (ed) monitoring:
- BP q15 min during acute titration first 4h then hourly (Fugate Lancet Neurol 2015 PMID 26184985)
- GCS q30 min × 4h then q1h (Fugate Lancet Neurol 2015 PMID 26184985)
- Repeat CT if any new neuro deterioration (rule out hemorrhage complication) (Fugate Lancet Neurol 2015 PMID 26184985)
- Ionized Ca + Mg if MgSO4 infusion (Triplett Pract Neurol 2022 PMID 35046115)

Follow-up plan: Neurology clinic 4-6 wk; repeat MRI 1-3 mo for resolution; long-term recurrence prevention (BP control if HTN-PRES, avoid CNI re-challenge or use mTOR alternative, avoid future bevacizumab if oncology-PRES, pre-pregnancy counselling if eclampsia-PRES); AED duration 3-12 mo per seizure recurrence + EEG; mood / cognition screen — post-PRES cognitive deficits described in cytotoxic variant (Triplett Pract Neurol 2022 PMID 35046115; Fischer/Schmutzhard J Neurol 2017 PMID 28054130)
- Close-out criterion: Long-term anti-trigger plan documented

Monitoring phase: Hourly BP early; daily neuro exam; serial Ca/Mg/Cr; cEEG if AMS persists; repeat MRI at 1-3 mo to confirm edema resolution (radiologic confirmation of diagnosis) (Bartynski AJNR 2008 PMID 18403560; Fugate Lancet Neurol 2015 PMID 26184985)

Disposition

Current setting: ed — Recognise PRES in headache + AMS + visual + seizure + severe HTN OR chemo/immunosuppressant trigger; STAT MRI FLAIR/DWI; initiate BP control (nicardipine/labetalol) targeting SBP 140-150; AED for seizure; ICU triage if severe (Fugate Lancet Neurol 2015 PMID 26184985)

Disposition criteria:
- Neuro-ICU for status epilepticus / GCS<13 / cytotoxic-PRES / hemorrhage / refractory HTN / eclampsia (Fugate Lancet Neurol 2015 PMID 26184985)
- Stroke / neurology unit for stable mild-moderate PRES on oral antihypertensive + AED (Fugate Lancet Neurol 2015 PMID 26184985)
- L&D / OB-ICU if peripartum eclampsia-PRES (Triplett Pract Neurol 2022 PMID 35046115)

Escalation triggers (move to higher acuity):
- GCS ≤8 → intubate + ICU (Fugate Lancet Neurol 2015 PMID 26184985)
- Status epilepticus → ICU + cEEG + escalate AED (Fugate Lancet Neurol 2015 PMID 26184985)
- Cytotoxic-PRES on DWI (DWI restriction) → ICU + neuro-IR readiness (Bartynski AJNR 2008 PMID 18403560)
- Intracranial hemorrhage on imaging → neurosurgery + protocol.ich (Fugate Lancet Neurol 2015 PMID 26184985)
- Refractory severe HTN despite two agents → ICU + arterial line + nicardipine + labetalol combination (Fugate Lancet Neurol 2015 PMID 26184985)
- Eclampsia + non-reassuring fetal tracing → STAT delivery (Triplett Pract Neurol 2022 PMID 35046115)

Patient Action Plan

**PRES recurrence-prevention + symptom-recognition action plan**
Personalised values: original_trigger, oral_antihypertensive_regimen, aed_regimen, follow_up_MRI_date, pregnancy_postpartum_status.

**Doing well — stable on antihypertensive + AED** (green):
Triggers:
- no_headache
- no_visual_changes
- no_new_seizure
- home_BP_in_range
- AED_doses_not_missed
Actions:
- Continue antihypertensive + AED as prescribed
- Keep neurology + primary-care + MRI follow-up appointments
- Avoid the original trigger drug if drug-PRES (do NOT re-start without neurology approval)
- Continue home BP log if HTN-PRES

**Caution — call neurology / primary care same day** (yellow):
Triggers:
- new_persistent_headache_>24h
- mild_visual_blurring
- home_SBP_>160_or_<100
- missed_AED_dose
- planned_surgery_or_pregnancy
Actions:
- Call neurology / primary care same day
- Do NOT stop AED without instruction
- Bring medication list to clinic call
- If pregnancy planned/confirmed, call BEFORE any medication change

**Emergency — call 911 / go to ED** (red):
Triggers:
- new_seizure
- sudden_visual_loss_or_double_vision
- severe_headache_with_AMS
- loss_of_consciousness
- new_focal_weakness_or_speech_difficulty
- severe_HTN_at_home_SBP_>200
- pregnant_with_severe_headache_or_visual_changes
Actions:
- Call 911 / go to nearest ED
- Bring medication list
- Tell ED you have a history of PRES and what your original trigger was
Contact provider when:
- Any red-zone trigger
- After any ED visit so neurology team is updated

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Status epilepticus in PRES — clinical or electrographic (Fugate Lancet Neurol 2015 PMID 26184985)
- [LIFE_THREATENING] Cerebral hemorrhage on initial or follow-up imaging (10-15% of PRES) (Fugate Lancet Neurol 2015 PMID 26184985)
- [LIFE_THREATENING] Peripartum / postpartum PRES with eclampsia phenotype (HTN + proteinuria + seizure) (Triplett Pract Neurol 2022 PMID 35046115)

Citations

- Fugate/Rabinstein Lancet Neurol 2015 PRES review (PMID 26184985) + Hinchey NEJM 1996 original description (PMID 8559202) + Bartynski AJNR 2008 imaging/pathophys (PMID 18403560) + Triplett Pract Neurol 2022 modern review (PMID 35046115) + Fischer/Schmutzhard J Neurol 2017 mechanisms review (PMID 28054130) [PMID:8559202](https://pubmed.ncbi.nlm.nih.gov/8559202/)
- Cited evidence (PMID 26184985) [PMID:26184985](https://pubmed.ncbi.nlm.nih.gov/26184985/)
- Cited evidence (PMID 18403560) [PMID:18403560](https://pubmed.ncbi.nlm.nih.gov/18403560/)
- Cited evidence (PMID 35046115) [PMID:35046115](https://pubmed.ncbi.nlm.nih.gov/35046115/)
- Cited evidence (PMID 28054130) [PMID:28054130](https://pubmed.ncbi.nlm.nih.gov/28054130/)

Last reconciled with current guidelines: 2026-05-26.
References
  • Fugate/Rabinstein Lancet Neurol 2015 PRES review (PMID 26184985) + Hinchey NEJM 1996 original description (PMID 8559202) + Bartynski AJNR 2008 imaging/pathophys (PMID 18403560) + Triplett Pract Neurol 2022 modern review (PMID 35046115) + Fischer/Schmutzhard J Neurol 2017 mechanisms review (PMID 28054130) — PMID:8559202
  • Cited evidence (PMID 26184985) — PMID:26184985
  • Cited evidence (PMID 18403560) — PMID:18403560
  • Cited evidence (PMID 35046115) — PMID:35046115
  • Cited evidence (PMID 28054130) — PMID:28054130